Literature DB >> 25288086

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.

Stephan A Kohlhoff1, Michael D Huband2, Margaret R Hammerschlag3.   

Abstract

The in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml).
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25288086      PMCID: PMC4249501          DOI: 10.1128/AAC.03920-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  P M Roblin; W Dumornay; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 2.  Treatment of chlamydial infections.

Authors:  Margaret R Hammerschlag; Stephan A Kohlhoff
Journal:  Expert Opin Pharmacother       Date:  2012-02-09       Impact factor: 3.889

3.  High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Authors:  Susanne Jacobsson; Daniel Golparian; Richard A Alm; Michael Huband; John Mueller; Jorgen Skov Jensen; Makoto Ohnishi; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

4.  Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

Authors:  S Block; J Hedrick; M R Hammerschlag; G H Cassell; J C Craft
Journal:  Pediatr Infect Dis J       Date:  1995-06       Impact factor: 2.129

  5 in total
  11 in total

1.  In Vitro Activity of Omadacycline against Chlamydia pneumoniae.

Authors:  Stephan A Kohlhoff; Natalia Huerta; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy; Michael D Huband
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017).

Authors:  Susanne Jacobsson; Ranmini Kularatne; Rossaphorn Kittiyaowamarn; Venessa Maseko; Porntip Paopang; Pongsathorn Sangprasert; Pachara Sirivongrangson; Laura Piddock; Teodora Wi; Emilie Alirol; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.

Authors:  Magnus Unemo; Johan Ringlander; Catherine Wiggins; Hans Fredlund; Susanne Jacobsson; Michelle Cole
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

5.  In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Authors:  Michael D Huband; Patricia A Bradford; Linda G Otterson; Gregory S Basarab; Amy C Kutschke; Robert A Giacobbe; Sara A Patey; Richard A Alm; Michele R Johnstone; Marie E Potter; Paul F Miller; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

6.  In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Authors:  Douglas J Biedenbach; Michael D Huband; Meredith Hackel; Boudewijn L M de Jonge; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

7.  Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections.

Authors:  Michelle M Butler; Samanthi L Waidyarachchi; Kristie L Connolly; Ann E Jerse; Weirui Chai; Richard E Lee; Stephan A Kohlhoff; Dean L Shinabarger; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.

Authors:  Lori M Newman; Martin Kankam; Aya Nakamura; Tom Conrad; John Mueller; John O'Donnell; Blaire L Osborn; Kenan Gu; George A Saviolakis
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

9.  Amphipathic β2,2-Amino Acid Derivatives Suppress Infectivity and Disrupt the Intracellular Replication Cycle of Chlamydia pneumoniae.

Authors:  Leena Hanski; Dominik Ausbacher; Terttu M Tiirola; Morten B Strøm; Pia M Vuorela
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

10.  Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.

Authors:  Pan F Chan; Velupillai Srikannathasan; Jianzhong Huang; Haifeng Cui; Andrew P Fosberry; Minghua Gu; Michael M Hann; Martin Hibbs; Paul Homes; Karen Ingraham; Jason Pizzollo; Carol Shen; Anthony J Shillings; Claus E Spitzfaden; Robert Tanner; Andrew J Theobald; Robert A Stavenger; Benjamin D Bax; Michael N Gwynn
Journal:  Nat Commun       Date:  2015-12-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.